YL135_PLAF7
ID YL135_PLAF7 Reviewed; 1560 AA.
AC Q8I5I1; A0A143ZZX1;
DT 16-DEC-2008, integrated into UniProtKB/Swiss-Prot.
DT 01-MAR-2003, sequence version 1.
DT 03-AUG-2022, entry version 72.
DE RecName: Full=Uncharacterized protein PF3D7_1223600;
GN ORFNames=PF3D7_1223600, PFL1135c;
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Sar; Alveolata; Apicomplexa; Aconoidasida; Haemosporida;
OC Plasmodiidae; Plasmodium; Plasmodium (Laverania).
OX NCBI_TaxID=36329;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=3D7;
RX PubMed=12368864; DOI=10.1038/nature01097;
RA Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W.,
RA Carlton J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K.D.,
RA Eisen J.A., Rutherford K.M., Salzberg S.L., Craig A., Kyes S., Chan M.-S.,
RA Nene V., Shallom S.J., Suh B., Peterson J., Angiuoli S., Pertea M.,
RA Allen J., Selengut J., Haft D., Mather M.W., Vaidya A.B., Martin D.M.A.,
RA Fairlamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A., McFadden G.I.,
RA Cummings L.M., Subramanian G.M., Mungall C., Venter J.C., Carucci D.J.,
RA Hoffman S.L., Newbold C., Davis R.W., Fraser C.M., Barrell B.G.;
RT "Genome sequence of the human malaria parasite Plasmodium falciparum.";
RL Nature 419:498-511(2002).
RN [2] {ECO:0000305}
RP SYNTHESIS OF 329-355, DEVELOPMENTAL STAGE, AND POSSIBLE CANDIDATE MALARIA
RP EPITOPE.
RX PubMed=17653272; DOI=10.1371/journal.pone.0000645;
RA Villard V., Agak G.W., Frank G., Jafarshad A., Servis C., Nebie I.,
RA Sirima S.B., Felger I., Arevalo-Herrera M., Herrera S., Heitz F.,
RA Baecker V., Druilhe P., Kajava A.V., Corradin G.;
RT "Rapid identification of malaria vaccine candidates based on alpha-helical
RT coiled coil protein motif.";
RL PLoS ONE 2:E645-E645(2007).
CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000255}; Multi-pass membrane
CC protein {ECO:0000255}.
CC -!- DEVELOPMENTAL STAGE: Expressed during the asexual cell-cycle on the
CC cell surface of the host erythrocytes. {ECO:0000269|PubMed:17653272}.
CC -!- BIOTECHNOLOGY: Possible candidate for an effective malaria vaccine as
CC determined by epitope response in sera. {ECO:0000269|PubMed:17653272}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; LN999947; CZT99395.1; -; Genomic_DNA.
DR RefSeq; XP_001350633.1; XM_001350597.1.
DR AlphaFoldDB; Q8I5I1; -.
DR STRING; 5833.PFL1135c; -.
DR PRIDE; Q8I5I1; -.
DR EnsemblProtists; CZT99395; CZT99395; PF3D7_1223600.
DR GeneID; 811279; -.
DR KEGG; pfa:PF3D7_1223600; -.
DR VEuPathDB; PlasmoDB:PF3D7_1223600; -.
DR HOGENOM; CLU_251252_0_0_1; -.
DR InParanoid; Q8I5I1; -.
DR OMA; IYFKINC; -.
DR PhylomeDB; Q8I5I1; -.
DR Proteomes; UP000001450; Chromosome 12.
DR GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR GO; GO:0030688; C:preribosome, small subunit precursor; IEA:InterPro.
DR GO; GO:0006364; P:rRNA processing; IEA:InterPro.
DR InterPro; IPR010301; RRP1-like.
DR PANTHER; PTHR13026; PTHR13026; 1.
PE 1: Evidence at protein level;
KW Coiled coil; Membrane; Merozoite; Reference proteome; Transmembrane;
KW Transmembrane helix.
FT CHAIN 1..1560
FT /note="Uncharacterized protein PF3D7_1223600"
FT /id="PRO_0000356834"
FT TRANSMEM 1271..1291
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 1314..1334
FT /note="Helical"
FT /evidence="ECO:0000255"
FT REGION 1..46
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 568..594
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COILED 36..60
FT /evidence="ECO:0000255"
FT COILED 317..359
FT /evidence="ECO:0000255"
FT COILED 1188..1239
FT /evidence="ECO:0000255"
FT COMPBIAS 25..46
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ SEQUENCE 1560 AA; 188237 MW; 3BAFE2E222FB4EEB CRC64;
MEEIENAHYQ NLENFNDETS EDVNDTSDDI NKNNDDNNKY DDNNVNVLDD KNKLENEEDN
NNNDNMMIFS SILRYQRYKT KKGNIYFDFK NTNLSLNEKD MLVQSSNFYH LFDIKSLLCP
HIYLNVSSHI NINISDYKNY LKRILNNDNV LDDKNENVKY SSCQEFIFEA VEQAEHIEVF
TKVQIVKKLF LFLNQNVAEK MKNYIDNIPI INSNDYVLVQ TNLKNDLLLG YVKGIKYNLF
FEILNMKKCF HSFLNENIVI YEINEDKEGY FKTIDGKKYL KEQIVYEKKD LLKNLDFYSM
YYCDYYFSSN SIIELEKKNN NNINCVNNNI NSVNNNINSV DNNINNVDNN INSVNNNNNI
SDKITHKFEY NDYNDIHLFF SFNICIKSVK NNLFLHIIYN DNNLKNGDEY LNETFPHYEE
LNLYNKQFDI NKMDKNLFKS NTFFINNLYY HLKCKLLCVF KFINMSDDDF MTDIHISQIK
KRRYVNEQDS YMLYTFNIHT LSNEGMVYIF FCNLYISNMF KENNFEIRVH TYLHFQLNKQ
NSYKKLKLIK YSSKFLYSLC FKEKSDSKKK KKKNDHHERD SDNNNNDSNN NNYYNSNNNS
NYCGSNNIIY GHDENFIFNS CDFNTLDQIK SGNYLIKDET INENFIFEVR NYKYTFILIS
SKCNIIIITL RKKKRKEEYN KKMSKYSSCS LNENVYMEGV EILNYCSSNN KNTNNIICNT
IINKYNYEIN NNIKNKNKSY ILFEIVCFYE NGEIQKYIYT CSLKNGNFEF FLNVKEDEKT
KSINCKKCFF KPILFPFNEE LLNKTKSSND LVLYNIKLSH FKNLIYIYFQ EKKIEGISLT
INNECLIINY IKMVSKLLKK ILQNLYNSDD IDIVYNFQHN TKNKCNYLSQ NVNIPSDNTI
SNVIKKNEMD NNDIKYNLFT QREVKSSFFE FKYILFGFYD LFLMNQKNYT DLNEKKKEEY
KKKNFINCFD SHSHYNFLNI IKEYINYDYI IDKCSYNISN DTQKKKKIKL NFYYFLLIIQ
YFKNTYTQEK KRSFFYMVYN ELLQRDKYLK HFYYTYHEID RKTNMHLNHN DNNIDTKEAK
KNEETELILK NVNFYDNYEL INIRKYDVIL FCFLFHMYNF CLKQNGLSND EFNSHITYFL
INKKMKKYKK KYRYISKKKI DTNEKNDDNN NINVCDSKNY KGTKNFDDTT NNILNKQNES
LDNLKKNMYL SKNNYDNQLS SYKNTKQNKT NINEKYNNNN IIMNYLTWKK CLYYIYKIKK
YTRKIETHEG LYISSMLYIN IYLCQIFFIL LNILRINNTN IYTNIHFDIR KNNLDYFYLL
ILLNFYSLFY ILISDQKYIL HEEENDTYIS KNIDNKEQMA NDKNIISLLS FFNNIYEQNK
EGMLKNDQNK NNHNTKTDIL YMSSSGMNIS INTPFLEKYL ILIYNIIKDK INIVKEDNYI
MEKLFFKINC MICNKVCVTN IYNNYYICEN NHIFNKCMLT FGCIYKNHII LPTIYLLHDI
NDKLFPINND HILSYNLQYE LDYIYFCSFC YNFITTQNSF YKKFFLFNQC PFCNHELNIL
